Other monoclonal antibody drugs targeting EGFR, such as nimotuzumab and cetuximab, also showed satisfactory clinical benefits and a manageable safety profile for advanced or recurrent/metastatic NPC [40, 41]. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.